North America Multifocal IOLs Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

North America Multifocal IOLs Market Size

• The North America multifocal IOLs market size was valued at USD 372.97 million in 2024 and is expected to reach USD 650.47 million by 2032, at a CAGR of7.20% during the forecast period
• The North America multifocal intraocular lenses (IOLs) market is experiencing robust growth, driven by rising awareness of advanced ophthalmic solutions and the increasing prevalence of age-related vision conditions such as cataracts and presbyopia. Early diagnosis, along with access to high-quality surgical care, is enabling timely and targeted vision correction across the region, particularly in the U.S. and Canada
• Technological advancements in ophthalmic surgery, such as femtosecond laser-assisted cataract surgery (FLACS) and image-guided systems, are significantly contributing to improved surgical outcomes and growing acceptance of multifocal IOLs. These innovations are enhancing patient satisfaction by reducing dependence on spectacles post-surgery

North America Multifocal IOLs Market Analysis

• Multifocal intraocular lenses (IOLs), designed to correct presbyopia and cataracts by enabling clear vision at multiple distances, are witnessing strong adoption across North America, driven by an aging population, rising cataract surgery volumes, and growing demand for spectacle independence among older adults. Technological improvements in surgical precision and lens materials are also encouraging wider use in ophthalmic practices
• The rising preference for premium IOLs over traditional monofocal lenses in North America is largely fueled by heightened patient awareness, the availability of advanced lens technologies—such as diffractive optics and extended depth-of-focus (EDOF) lenses—and increasing disposable incomes. In addition, favorable insurance coverage for standard cataract procedures is encouraging patients to upgrade to multifocal IOLs for enhanced visual outcomes
• U.S. dominated the North America Multifocal IOLs market, accounting for the largest revenue share of 35.2% in 2024. This dominance is attributed to its well-established ophthalmic care infrastructure, high volume of cataract surgeries, and rapid integration of premium intraocular lens technologies across ambulatory surgery centers and hospitals. In addition, the presence of major IOL manufacturers, robust reimbursement systems, and growing demand for spectacle-free solutions post-surgery are driving consistent market expansion
• Canada is projected to register the fastest CAGR of 11.8% in the North America multifocal IOLs market during the forecast period, supported by its expanding aging population, improved access to eye care services, and increased public and private funding for vision correction procedures
• Non Reduction lenses dominated the Asia-Pacific multifocal IOLs market with a market share of 66.4% in 2024, driven by their widespread clinical preference, simplicity in design, and cost-effectiveness, making them a standard choice in multifocal IOL procedures across Asia-Pacific

Report Scope and North America Multifocal IOLs Market Segmentation      

North America Multifocal IOLs Market Trends

Growing Therapeutic Advancements and Increasing Clinical Research

• A significant and accelerating trend in the North America Multifocal IOLs market is the increasing focus on therapeutic innovations and clinical research—particularly addressing complex visual impairments through improved IOL designs and neurosensory integration
  • For instance, various medical device companies and research institutes across North America are investing in next-generation multifocal intraocular lenses that incorporate enhanced diffractive optics, extended depth-of-focus (EDOF) mechanisms, and light-adjustable technologies. These developments aim to deliver sharper vision with reduced side effects such as halos or glare, which are commonly associated with older multifocal lenses
• The increasing adoption of personalized eye care models across specialty clinics and surgical centers is enabling better visual outcomes. These models use advanced preoperative diagnostics like wavefront aberrometry and ocular biometry to optimize lens selection based on individual ocular anatomy and lifestyle needs
• Partnerships between medical technology firms, university hospitals, and government-backed programs are also helping to expand access to premium intraocular lenses by improving reimbursement structures, streamlining import regulations, and boosting physician training
• As North America continues to prioritize precision eye care and value-based health outcomes, the Multifocal IOLs market is poised for sustained growth—driven by innovation, improved surgical precision, and a rising demand for spectacle-free vision among aging populations

North America Multifocal IOLs Market Dynamics

Driver

Growing Need Due to Rising Diagnosis Rates and Advancements in Genetic Research

•  The increasing prevalence of multifocal intraocular lens (IOLs) procedures across North America, supported by enhanced awareness and advancements in diagnostic capabilities, is significantly driving market growth. The region is witnessing a rise in cataract and presbyopia cases, especially among the aging population, leading to a growing demand for early surgical interventions. The widespread adoption of routine eye examinations and availability of specialized ophthalmic clinics are enabling earlier detection and timely treatment of visual impairments, further supporting the market expansion
  • For instance, in April 2024, Anavex Life Sciences reported positive progress in its Phase III clinical trial for Anavex 2-73 (blarcamesine), a small molecule aimed at treating visual impairments through sigma-1 receptor activation. This and other late-stage developments are anticipated to accelerate the North America Multifocal IOLs market during the forecast period
• Growing interest in disease-modifying therapies and next-generation IOL designs is prompting a shift away from standard symptomatic correction toward more customized and curative solutions, including light-adjustable lenses and extended-depth-of-focus (EDOF) lenses
• The Asia-Pacifican Medicines Agency (EMA) continues to play a pivotal role by offering orphan drug incentives, accelerated reviews, and R&D grants to companies innovating within the ophthalmic and rare disease treatment space
• Collaborations among biotech firms, academic institutions, and vision health foundations are also fostering a robust research ecosystem across Asia-Pacific. These partnerships are helping to scale patient registries, awareness initiatives, and clinical trial participation—critical steps in improving access and long-term care strategies

Restraint/Challenge

Limited Infrastructure and Variability in Clinical Adoption

• The high treatment cost associated with advanced Multifocal IOLs—including premium lens implants, gene therapies, and customized diagnostics—poses a substantial barrier to widespread adoption, especially in Eastern North America and rural areas with limited healthcare funding
• Even when granted orphan drug status, these therapies typically involve lengthy and expensive development cycles with sophisticated manufacturing requirements, making them less affordable for national health systems with constrained budgets
• Moreover, specialized multidisciplinary care, which includes ophthalmologists, optometrists, genetic counselors, and rehabilitation therapists, is often concentrated in urban centers. This geographic disparity forces patients and families to travel long distances or endure long wait times for specialized services
• Another challenge is the lack of standardized protocols for fitting and managing advanced Multifocal IOLs. Due to limited clinical data and physician familiarity—especially in low-volume centers—the adoption of innovative solutions remains inconsistent
• To overcome these challenges, policy reforms, enhanced government funding, cross-border research collaboration, and the establishment of dedicated ophthalmology hubs across North America will be essential in expanding access and achieving sustainable growth in the North America Multifocal IOLs Market

North America Multifocal IOLs Market Scope

The market is segmented on the basis of type, design, packaging, product type, brand, incision size, pupil dependence, power, material, adjustability, price range, flexibility, age group, gender, application, end user, and distribution channel.

• By Type

On the basis of type, the multifocal IOLs market is segmented into soft lens and rigid gas permeable (RGP or Hard) Lens. The soft lens segment dominated the market with the largest revenue share of 68.3% in 2024, owing to their high comfort, wide adoption, and ease of use.

The rigid gas permeable lens segment is expected to grow at the fastest CAGR of 7.5% from 2025 to 2032, due to increasing demand for sharper vision correction and long-lasting lens material.

• By Design

On the basis of design, the multifocal IOLs market is segmented into simultaneous vision lenses and segmented multifocal lenses. Simultaneous Vision Lenses led the segment with 61.9% share in 2024, favored for their ability to provide vision at multiple distances simultaneously.

The Segmented Multifocal Lenses segment is expected to witness the highest CAGR of 6.9% during 2025–2032, due to increased customization and suitability for post-cataract patients.

• By Packaging

On the basis of packaging, the multifocal IOLs market is segmented into packaging into Pack of 6, Pack of 30, and Others. The Pack of 6 segment held the largest market share at 47.6% in 2024, due to affordability and common use for short-term needs.

The Pack of 30 segment is projected to grow at the fastest CAGR of 8.1% from 2025 to 2032, as it supports long-term usage and bulk purchases by clinics.

• By Product Type

On the basis of product type, the multifocal IOLs market is segmented into Diffractive Multifocal IOLs, Hybrid Multifocal IOLs, and Refractive Multifocal IOLs. The Diffractive Multifocal IOLs segment led the market with 42.8% share in 2024, owing to consistent visual outcomes and wide clinical usage.

Hybrid Multifocal IOLs are expected to grow at the fastest CAGR of 9.3% from 2025 to 2032, driven by innovation and combining benefits of both diffractive and refractive technologies.

• By Brand

On the basis of brand, the multifocal IOLs market is segmented into Technis Symphony, Zeiss Trifocal, and Others. Zeiss Trifocal held the largest share at 35.1% in 2024, supported by strong brand trust, innovative lens design, and wide availability.

The Technis Symphony segment is forecasted to grow at the highest CAGR of 7.8% from 2025 to 2032, due to increasing preference in premium lens surgeries.

• By Incision Size

On the basis of incision size, the multifocal IOLs market is segmented into 1.8 MM, 2.2 MM, and Others. 2.2 MM held the dominant market share of 54.6% in 2024, as it balances ease of insertion and surgical control.

The 1.8 MM segment is expected to witness the fastest CAGR of 8.5% from 2025 to 2032, due to a rising shift toward micro-incision cataract surgeries.

• By Pupil Dependence

On the basis of pupil dependence, the multifocal IOLs market is segmented into dependent and independent. Independent pupil lenses dominated the market with 63.2% share in 2024, valued for their effectiveness across variable light conditions.

The Dependent pupil segment is projected to grow at a CAGR of 6.7% from 2025 to 2032, as product refinements reduce their light condition limitations.

• By Power

On the basis of power, the multifocal IOLs market is segmented into low power and high power. Low Power lenses accounted for the largest share at 58.9% in 2024, suitable for patients with minimal refractive correction needs.

High Power lenses are expected to grow at the fastest CAGR of 7.6% from 2025 to 2032, due to rising demand in post-surgical and high-prescription use cases.

• By Material

On the basis of material, the multifocal IOLs market is segmented into Hydrophobic Acrylic, Silicon & Collamer, Lehfilcon-A, Somofilcon A, and Others. The Hydrophobic Acrylic segment held the largest market share of 49.5% in 2024, driven by its superior biocompatibility, high optical clarity, and a reduced risk of posterior capsule opacification (PCO), making it a preferred choice for long-term implantation.

The Somofilcon A segment is projected to witness the fastest CAGR of 8.8% from 2025 to 2032, supported by its enhanced oxygen permeability and comfort, particularly suitable for soft contact lens-based intraocular applications.

• By Adjustability

On the basis of adjustability, the multifocal IOLs market is segmented into light reduction and non reduction. The Non Reduction lenses segment dominated the market with a share of 66.4% in 2024, owing to their widespread adoption, consistent light transmission, and ease of manufacturing, which cater to standard post-cataract correction needs.

The Light Reduction lenses segment is expected to grow at the fastest CAGR of 9.1% from 2025 to 2032, fueled by innovations in photoadaptive materials that provide dynamic visual adjustments under different lighting conditions, improving patient comfort and outcomes.

• By Price Range

On the basis of price range, the multifocal IOLs market is segmented into Premium Lens and Standard Lens. The Premium Lens segment captured the largest revenue share of 59.7% in 2024, driven by increasing demand from aging populations seeking advanced visual outcomes and a rise in disposable incomes enabling patients to opt for premium surgical interventions.

The Standard Lens segment is projected to grow at the fastest CAGR of 8.4% from 2025 to 2032, due to growing access in public healthcare systems and greater affordability, particularly in emerging economies.

• By Flexibility

On the basis of flexibility, the market is segmented into Foldable IOLs and Rigid IOLs. The Foldable IOLs segment led with a market share of 73.5% in 2024, owing to their dominance in micro-incision cataract surgeries, which enable faster recovery and reduced postoperative complications.

The Rigid IOLs segment is anticipated to grow at a CAGR of 5.9% from 2025 to 2032, sustained by their limited use in specific ophthalmic procedures where higher structural rigidity is required.

• By Age Group

On the basis of age group, the multifocal IOLs market is segmented into Above 51 Years, 41–50 Years, and Below 40 Years. The Above 51 Years segment held the highest share of 67.2% in 2024, driven by a higher prevalence of age-related visual conditions like cataract and presbyopia in the aging population.

The 41–50 Years segment is expected to grow at the fastest CAGR of 7.2% from 2025 to 2032, attributed to increasing early intervention through elective vision correction procedures and rising adoption of premium lens technologies in this age group.

• By Gender

On the basis of gender, the multifocal IOLs market is segmented into female and male. The female segment dominated the market with a share of 53.8% in 2024, due to higher life expectancy and increased healthcare engagement for routine eye exams and vision care.

The male segment is expected to grow at the fastest CAGR of 6.9% during the forecast period, supported by rising awareness and increased participation in elective vision correction among aging male demographics.

• By Application

On the basis of application, the multifocal IOLs market is segmented into Vision disorder, cataract, corneal disorder, and others. The cataract segment held the largest market share of 64.9% in 2024, as multifocal IOLs are predominantly used post-cataract surgery to restore vision across multiple distances, eliminating the need for glasses.

The corneal disorder segment is projected to grow at the fastest CAGR of 8.7% from 2025 to 2032, driven by a growing number of corrective corneal procedures and lens innovations tailored for corneal irregularities.

• By End User

On the basis of end user, the multifocal IOLs market is segmented into hospitals, ophthalmology clinics, eye research institutes, ambulatory surgery centers, and others. The Hospitals segment dominated the market with a share of 45.6% in 2024, supported by comprehensive surgical infrastructure and a higher volume of IOL implant procedures.

The ophthalmology clinics segment is expected to grow at the fastest CAGR of 9.2% from 2025 to 2032, due to increasing preference for specialized outpatient care and rising investments in clinic-based surgical suites.

• By Distribution Channel

On the basis of distribution channel, the multifocal IOLs market is segmented into direct tender, retail sales, and others. The direct tender segment held the largest share of 48.1% in 2024, driven by centralized procurement of IOLs through public hospitals and government-funded institutions.

The retail sales segment is expected to grow at the fastest CAGR of 10.3% from 2025 to 2032, driven by the emergence of online optical retailers, increased patient awareness, and growing access to lens prescriptions and customization options.

North America Multifocal IOLs Market Regional Analysis

• North America dominated the global multifocal intraocular lenses (IOLs) market with the largest revenue share of 30.3% in 2024, driven by the region's advanced ophthalmic healthcare infrastructure, rising prevalence of presbyopia and cataracts, and rapid adoption of premium lens technologies
• Strong regulatory frameworks, widespread reimbursement policies, and high patient awareness are fostering growth across both public and private healthcare sectors
• Increased government funding for vision health, along with public-private initiatives to reduce cataract surgery backlogs post-COVID, is propelling the use of advanced multifocal IOLs. Furthermore, North America hosts several leading ophthalmic device manufacturers and R&D centers, facilitating continuous product innovation and clinical evaluation

U.S. North America Multifocal IOLs Market Insight

The U.S. multifocal IOLs market accounted for the largest share within North America at 36.1% in 2024, owing to its extensive adoption of premium lens technologies, high volume of cataract surgeries, and advanced ambulatory surgery center network. The presence of top ophthalmic device companies, robust FDA approval pathways, and increasing preference for lifestyle-enhancing procedures are driving consistent market expansion. Additionally, growing awareness of presbyopia correction and favorable reimbursement for advanced IOLs further support the U.S. market's leadership position.

Canada North America Multifocal IOLs Market Insight

The Canada multifocal IOLs market is expected to register the fastest CAGR of 11.6% from 2025 to 2032, driven by an aging population, improved access to ophthalmic care, and rising preference for spectacle independence post-surgery. The Canadian market is benefiting from shorter surgical wait times, increased private insurance coverage for premium lenses, and a growing network of outpatient ophthalmology clinics. Government initiatives to enhance cataract surgery efficiency and digital screening programs are also supporting widespread adoption of multifocal IOLs.

Mexico North America Multifocal IOLs Market Insight

The Mexico multifocal IOLs market is showing steady growth, fueled by public healthcare expansion, increasing ophthalmic surgical training, and rising demand for advanced visual correction technologies. Growth is particularly concentrated in urban centers, where private hospitals and specialty clinics are adopting premium lens implants to meet patient expectations. Cross-border medical tourism and collaborations with international manufacturers are further enhancing product availability and affordability for local patients.

 North America Multifocal IOLs Market Share

The North America Multifocal IOLs industry is primarily led by well-established companies, including:

• Johnson & Johnson and its affiliates (U.S.)
• Hoya Medical Singapore Pte. Ltd. (Singapore)
• Zeiss Group (Germany)
• Alcon Inc. (Switzerland)
• Rayner Group (U.K.)
• Lenstec, Inc. (U.S.)
• Aurolab (India)
• Excellent Hi-Care Pvt Ltd (India)
• Sav-Iol SA (Switzerland)
• Vsy Biotechnology GmbH (Germany)
• Hanita Lenses Ltd. (Israel)
• Care Group (India)
• Iolart (India)
• Omni Lens Pvt. Ltd. (India)
• Ophtec BV (Netherlands)

Latest Developments in North America Multifocal IOLs market

• In February 2025, Taysha Gene Therapies announced positive interim results from Part A of its Phase I/II clinical trial evaluating TSHA-102, an investigational gene therapy for Rett syndrome. The results showed no serious adverse events and dose-dependent clinical improvements, paving the way for a pivotal Part B study. The company is now working with global regulators to initiate expansion trials in pediatric populations and further validate its one-time gene therapy approach to address MECP2 mutations

• In June 2024, the ZEISS Group actively promotes eye health during Cataract Awareness Month by conducting educational campaigns and free eye screenings. Their initiatives aim to raise awareness about cataract prevention and treatment, emphasizing the importance of early detection and modern surgical solutions. ZEISS's efforts include partnerships with local healthcare providers to improve access to quality eye care and support communities in managing and preventing vision impairment
• In December 2024, Pfizer Inc. announced the successful completion of its acquisition of Seagen Inc., a North America biotechnology company known for discovering, developing, and commercializing transformative cancer medicines. Pfizer acquired all outstanding common stock of Seagen for USD 229 per share in cash, totalling In March 2023, The ZEISS Group design and innovate IOL and OVD Portfolio to address both patient needs and surgeon preferences. Combining innovation and precision, it offers a comprehensive selection of cataract consumables and implants, tailored for monofocal, toric, and refractive cataract surgeries
• In April 2024, Alcon, a leader in eye care dedicated to helping people see brilliantly, showcased approximately 100 company-supported and investigator-led data presentations demonstrating its latest innovative efforts aimed at optimizing patient outcomes at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 5-8 in Boston. In addition, the company hosts multiple peer-to-peer symposia and in-booth demonstrations of its industry-leading implantable and devices, including the Clareon intraocular lens (IOL) portfolio, cloud-based SMARTCataract surgical planner, Hydrus Microstent and more

SKU-72858